Longeveron Inc. Board of Directors

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Mr. Paul T. Lehr J.D.

Mr. Paul T. Lehr J.D.

International Executive Director, General Counsel & Secretary

Ms. Elly Ryu

Ms. Elly Ryu

VP & Corporate Controller

Dr. Dan Gincel Ph.D.

Dr. Dan Gincel Ph.D.

Senior Vice President of Strategic Collaborations & Scientific Affairs

Mr. Michael Mannarino

Mr. Michael Mannarino

VP & Corporate Controller

Ms. Lisa McClain-Moss

Ms. Lisa McClain-Moss

Vice President of Manufacturing

Mr. Brian G Rash Ph.D.

Mr. Brian G Rash Ph.D.

VP of Research & Discovery

Dr. Joshua Michael Hare FACC, M.D.

Dr. Joshua Michael Hare FACC, M.D.

Co-Founder, Chief Science Officer & Chairman

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.